Site icon OncologyTube

Larotrectinib Will Change TRK Fusion Treatment | Bring New 1st-in-Class Drugs to Patients

Scott Z. Fields, MD, Bayer Pharmaceuticals explains Larotrectinib Will Change TRK Fusion Treatment | Bring New 1st-in-Class Drugs to Patients at Annual Meeting 2018

Exit mobile version